A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Bone Health Technologies Raises $5M to Launch Bone Density Wearable

Bone Health Technologies

Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a new $5 million funding round from leading investment firms, including Esplanade Ventures, Berkeley Catalyst Fund, as well as strategic investor and leading global medical technology provider Terumo Medical. Ella Seitz of Esplanade Ventures and Yushin Yazaki of Terumo were appointed as board observers.

Pivotal Moment for the Company’s Mission

This influx of capital marks a pivotal moment in BHT’s mission to reshape bone health for postmenopausal women, closing right in time for de novo FDA clearance. The funding will support the final development stages of BHT’s flagship Osteoboost vibration wearable, expected to launch later this year.


Osteoboost is a smart wearable device, worn as a belt around the hips, that is clinically proven to protect postmenopausal women from the bone strength and bone density loss common with menopause and aging. Through the delivery of precision vibration, Osteoboost stimulates the natural mechanism of bone regeneration, reducing a user’s risk of progression from osteopenia to osteoporosis. During the trial, Osteoboost not only significantly slowed the loss of bone density but also had a high user adherence rate exceeding 80% and zero serious adverse events.

Laura Yecies, CEO of Bone Health Technologies.

Over 64 million people in the US are affected by osteopenia and osteoporosis today. Osteoboost is the first and only non-pharmacological FDA-cleared prescription device to address this $30 billion market. Currently, BHT is finalizing the manufacturing and distribution logistics for the first public release of Osteoboost, anticipated later this year. Patients and health professionals interested in following the launch progress are invited to join a notification list. “Bringing a breakthrough, de novo, prescription medical device to market is a challenging road that requires patience and perseverance. We chose to validate the science behind Osteoboost through a rigorous clinical trial, so that postmenopausal women and their physicians could have confidence in our data. The FDA clearance was the last major external hurdle, and now our focus shifts to the launch later this year. We’re thankful for our early investors who believed in our vision and our new investors who seized on the clinical data and recognized the impact we can have for women around the world.”

Ella Seitz, Partner at Esplanade Ventures, a new investor in Bone Health Technologies

“Osteopenia is a serious condition that affects 1 in 6 women in North America, and we believe that Osteoboost, as the first FDA-cleared noninvasive wearable device, can make a substantial improvement in the lives of millions of women. We’re excited for the future of the company and are honored to support Osteoboost’s journey to solving a critical chronic condition for women.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy